Kwality Pharmaceuticals Stock Screener | Share Price & Fundamental Analysis
KPL
Pharmaceuticals
Screen Kwality Pharmaceuticals share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price BSE
₹1175.70
▲
75.80 (6.89%)
Market Cap
₹1,172.57 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
3.98
EPS (TTM)
₹38.36
Dividend Yield
-
Debt to Equity
0.43
52W High
₹1194.50
52W Low
₹623.75
Operating Margin
22.00%
Profit Margin
12.82%
Revenue (TTM)
₹117.00
EBITDA
₹27.00
Net Income
₹15.00
Total Assets
₹447.00
Total Equity
₹262.00
Kwality Pharmaceuticals Share Price History - Stock Screener Chart
Screen KPL historical share price movements with interactive charts. Analyze price trends and patterns.
Kwality Pharmaceuticals Company Profile - Fundamental Screener
Screen Kwality Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for KPL shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE552U01010
Kwality Pharmaceuticals Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen KPL balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 447 | 394 | 354 | 341 | 166 | 133 | 105 | 96 | 71 | 51 |
| Current Assets | 284 | 243 | 207 | 228 | 106 | 89 | 75 | 75 | 53 | 38 |
| Fixed Assets | 146 | 139 | 121 | 92 | 57 | 43 | 29 | 20 | 17 | 13 |
| Liabilities | ||||||||||
| Total Liabilities | 447 | 394 | 354 | 341 | 166 | 133 | 105 | 96 | 71 | 51 |
| Current Liabilities | 15 | 20 | 29 | 21 | 28 | 20 | 8 | 6 | 4 | 3 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 262 | 223 | 199 | 180 | 60 | 45 | 36 | 29 | 25 | 21 |
| Share Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 5 | 5 |
| Reserves & Surplus | 254 | 214 | 190 | 171 | 51 | 36 | 27 | 19 | 20 | 17 |
Screen KPL income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun | 2022-Sept | 2022-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 117 | 112 | 112 | 93 | 80 | 90 | 85 | 70 | 68 | 70 | 79 | 66 | 71 | 57 | 57 |
| Expenses | 90 | 87 | 86 | 78 | 63 | 70 | 67 | 74 | 54 | 54 | 61 | 48 | 52 | 40 | 41 |
| EBITDA | 27 | 25 | 26 | 14 | 18 | 20 | 18 | -4 | 14 | 16 | 17 | 18 | 18 | 17 | 16 |
| Operating Profit % | 22.00% | 22.00% | 23.00% | 15.00% | 22.00% | 22.00% | 21.00% | -7.00% | 20.00% | 22.00% | 21.00% | 25.00% | 26.00% | 28.00% | 27.00% |
| Depreciation | 5 | 5 | 5 | 5 | 4 | 5 | 5 | 4 | 5 | 5 | 5 | 3 | 3 | 4 | 4 |
| Interest | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 3 | 1 | 1 | 1 | 2 |
| Profit Before Tax | 19 | 17 | 19 | 6 | 11 | 13 | 11 | -10 | 7 | 8 | 10 | 14 | 14 | 12 | 10 |
| Tax | 5 | 5 | 4 | 2 | 3 | 4 | 3 | -2 | 2 | 2 | 2 | 4 | 4 | 2 | 3 |
| Net Profit | 15 | 12 | 14 | 4 | 8 | 9 | 9 | -7 | 5 | 6 | 8 | 11 | 11 | 9 | 7 |
| EPS | 13.95 | 11.49 | 13.60 | 4.08 | 8.04 | 8.15 | 8.21 | -7.23 | 5.10 | 5.99 | 7.39 | 9.97 | 9.99 | 8.82 | 6.82 |
Kwality Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals
Screen KPL cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 53 | 43 | 41 | 61 | 27 | 6 | 14 | -1 | 4 | -3 |
| Investing Activities | -29 | -26 | -48 | -63 | -23 | -18 | -12 | -6 | -7 | -3 |
| Financing Activities | -14 | -17 | 1 | 6 | 1 | 12 | -2 | 5 | 5 | 6 |
| Net Cash Flow | 10 | -1 | -6 | 3 | 4 | 0 | 0 | -1 | 2 | 0 |
Screen KPL shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 54.83% | 54.83% | 54.83% | 54.83% | 54.83% | 54.83% | 54.83% | 54.77% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.33% | 0.33% | 0.32% | 0.03% | 0.02% | 0.00% | 0.00% | 0.01% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 33.68% | 33.32% | 33.39% | 33.25% | 32.78% | 31.78% | 31.70% | 32.95% |
| Other Holding | 11.16% | 11.52% | 11.47% | 11.90% | 12.38% | 13.40% | 13.47% | 12.27% |
| Shareholder Count | 11,595 | 10,115 | 9,420 | 8,947 | 7,487 | 5,273 | 5,695 | 5,786 |
Kwality Pharmaceuticals Dividend Screener - Share Yield Analysis
Screen KPL dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.00 | 0.00% |
| 2024-March | ₹0.00 | 0.00% |
| 2023-March | ₹0.00 | 0.00% |
| 2022-March | ₹0.00 | 0.00% |
| 2021-March | ₹0.00 | 0.00% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.60 | 1.46% |
Kwality Pharmaceuticals Index Membership - Market Screener Classification
Screen KPL by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Kwality Pharmaceuticals Market Events Screener - Corporate Actions
Screen KPL market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | 3.14% | ||
| Annual General Meeting | NA | -11.48% | ||
| 2025-11-13 | 2025-11-13 | Quarterly Result Announcement | NA | -1.90% |
| 2025-08-11 | 2025-08-11 | Quarterly Result Announcement | NA | 0.73% |
| 2025-05-19 | 2025-05-19 | Quarterly Result Announcement | NA | 12.45% |
| 2025-01-31 | 2025-01-31 | Quarterly Result Announcement | NA | -2.47% |
| 2024-10-30 | 2024-10-30 | Quarterly Result Announcement | NA | -0.73% |
| 2017-10-11 | 2017-10-12 | Bonus | 1:1 | - |
Kwality Pharmaceuticals Competitors Screener - Peer Comparison
Screen KPL competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 412,950 | 39.35 | 54,729 | 9.71% | 10,980 | 39.47 |
| Divis Laboratories | 168,413 | 68.31 | 9,712 | 18.67% | 2,191 | 44.14 |
| Torrent Pharmaceuticals | 130,247 | 60.76 | 11,539 | 6.99% | 1,911 | 62.90 |
| Cipla | 121,238 | 22.46 | 28,410 | 7.12% | 5,291 | 46.90 |
| Dr Reddys Laboratories | 104,613 | 18.49 | 33,741 | 16.73% | 5,725 | 43.77 |
| Lupin | 96,056 | 22.19 | 22,910 | 13.74% | 3,306 | 55.44 |
| Zydus Life Science | 92,075 | 18.30 | 23,511 | 18.55% | 4,615 | 44.07 |
| Mankind Pharma | 89,356 | 51.11 | 12,744 | 20.90% | 2,007 | 44.20 |
| Aurobindo Pharma | 69,290 | 20.05 | 32,346 | 9.43% | 3,484 | 49.09 |
| Alkem Laboratories | 65,324 | 27.31 | 13,458 | 3.70% | 2,216 | 38.49 |
Kwality Pharmaceuticals Company Announcements - News Screener
Screen KPL latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-01-01 | Closure of Trading Window | View |
| 2025-12-01 | Intimation Of Change In Name Of Managing Director Of The Company | View |
| 2025-11-22 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-13 | Unaudited Financial Results For The Quarter And Half Year Ended 30-09-2025 | View |
| 2025-11-13 | Board Meeting Outcome for To Consider And Approve The Financial Results For The Quarter And Half Year Ended 30-09-2025 | View |
| 2025-11-06 | Successful Completion Of The EU-GMP Audit At Its Amritsar General And Beta-Lactam Units | View |
| 2025-11-05 | Board Meeting Intimation for Consideration And Approval Of Unaudited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended On 30Th September 2025. | View |
| 2025-10-11 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-09-27 | Closure of Trading Window | View |
| 2025-09-11 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | View |
| 2025-09-10 | Regularization And Reappointment Of Directors At AGM | View |
| 2025-09-09 | Appointment Of Secretarial Auditors Of The Company | View |
| 2025-09-09 | Shareholder Meeting / Postal Ballot-Outcome of AGM | View |
| 2025-08-22 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-08-22 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-08-18 | Kwality Pharma Receives Product Registration For Bleomycin 15 IU In Mexico For Sale And Distribution. | View |
| 2025-08-16 | Notice Of 42Nd AGM Of The Company Scheduled To Be Held On 09Th September 2025 | View |
| 2025-08-16 | Reg. 34 (1) Annual Report. | View |
| 2025-08-16 | Intimation Of Book Closure | View |
| 2025-08-16 | 42Nd Annual General Meeting (AGM) Of The Shareholders Of The Company Will Be Held On Tuesday The 09Th September 2025 At 12:00 Noon Through Video Conference (VC) / Other Audio Visual Means (OAVM) | View |